We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

119 hedge funds and large institutions have $738M invested in Karyopharm Therapeutics in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 37 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

10% more funds holding

Funds holding: 108 → 119 (+11)

0% more capital invested

Capital invested by funds: $737M → $738M (+$992K)

0.03% less ownership

Funds ownership: 4.8% → 4.77% (-0.03%)

8% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 37

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

68% less call options, than puts

Call options by funds: $1.14M | Put options by funds: $3.56M

Holders
119
Holders Change
+11
Holders Change %
+10.19%
% of All Funds
2.72%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
17
Increased
34
Reduced
37
Closed
6
Calls
$1.14M
Puts
$3.56M
Net Calls
-$2.42M
Net Calls Change
-$2.46M

Top Buyers

Rank Fund Capital Flow
1
CS
Candriam SCA
Luxembourg
+$10.9M
2
DM
Deerfield Management
New York
+$8.75M
3
Federated Hermes
Federated Hermes
Pennsylvania
+$5.41M
4
BlackRock
BlackRock
New York
+$3.78M
5
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
+$3.13M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$10.9M
2
State Street
State Street
Massachusetts
-$7.32M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.57M
4
Franklin Resources
Franklin Resources
California
-$4.85M
5
Goldman Sachs
Goldman Sachs
New York
-$4.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$4.63M +$269K +972 +6%
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$4.43M -$884K -3,199 -16%
Citadel Advisors
28
Citadel Advisors
Florida
$4.11M +$1.19M +4,317 +37%
Two Sigma Advisers
29
Two Sigma Advisers
New York
$4.06M +$1.51M +5,460 +52%
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$3.8M +$954K +3,450 +30%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$3.72M +$84.3K +305 +2%
DAM
32
Doheny Asset Management
California
$3.67M -$1.24M -4,500 -24%
FCM
33
Frontier Capital Management
Massachusetts
$3.48M -$1.89M -6,832 -33%
MOACM
34
Mutual of America Capital Management
New York
$2.3M -$372K -1,347 -13%
JP Morgan Chase
35
JP Morgan Chase
New York
$2.08M +$5.25K +19 +0.2%
SH
36
Sandia Holdings
Connecticut
$2.04M – – –
USAA
37
United Services Automobile Association
Texas
$1.93M – – –
Allianz Asset Management
38
Allianz Asset Management
Germany
$1.85M +$180K +652 +10%
PAM
39
Panagora Asset Management
Massachusetts
$1.79M -$2.35M -8,503 -55%
CIA
40
Capital Impact Advisors
Massachusetts
$1.74M +$1.88M +6,800 New
MCM
41
Moore Capital Management
New York
$1.7M -$921K -3,333 -33%
Morgan Stanley
42
Morgan Stanley
New York
$1.69M -$167K -605 -8%
Swiss National Bank
43
Swiss National Bank
Switzerland
$1.45M – – –
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$1.26M -$553 -2 -0%
Bank of America
45
Bank of America
North Carolina
$1.21M -$105K -381 -7%
Renaissance Technologies
46
Renaissance Technologies
New York
$1.2M -$1.24M -4,480 -49%
Barclays
47
Barclays
United Kingdom
$1.06M +$651K +2,356 +131%
SIM
48
Spark Investment Management
New York
$1.06M +$1.14M +4,140 New
AllianceBernstein
49
AllianceBernstein
Tennessee
$1.05M – – –
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$918K – – –
1
2
3 4 5

KPTI Hedge Fund Activity: Q3 2018 in Review

119 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2018, worth a combined $738M — up 0.13% from $737M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new KPTI positions and 6 closed out — a net gain of 11 holders — while 34 added to existing stakes and 37 trimmed.

The largest buyer was Candriam SCA, adding an estimated $10.9M. The largest seller was Point72 Asset Management, cutting an estimated $10.9M.

  • 119 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2018, up from 108 in Q2 2018.
  • Funds reported $738M of Karyopharm Therapeutics stock for Q3 2018, up 0.13% quarter-over-quarter.
  • 17 funds opened new Karyopharm Therapeutics positions in Q3 2018 and 6 closed out, a net change of +11 holders.
  • The largest Karyopharm Therapeutics buyer in Q3 2018 was Candriam SCA, an estimated $10.9M added.
  • The largest Karyopharm Therapeutics seller in Q3 2018 was Point72 Asset Management, an estimated $10.9M sold.

Based on aggregated 13F filings for Q3 2018.